glp 1 incretin effect GLP-1 is released from the small intestine after meal ingestion and Incretins role in metabolic homeostasis

Combined with the theory of GIP being an obesogenic hormone (53), these prior findings have highlighted the potential of GIP receptor antagonism, and today the development of GIP receptor antagonists has also emerged as an attractive therapeutic approach for addressing obesity and cardiovascular diseases (54, 55)

Jastreboff AM, Kaplan LM, Fras JP, Wu Q, Du Y, Gurbuz S, Coskun T, Haupt A, Milicevic Z, Hartman ML (2023) Triple-hormone-receptor agonist retatrutide for obesity a phase 2 trial

Metabolic rate decreases after weight loss, a phenomenon called metabolic adaptation

Services Mercy Wellness Clinic provides complete medical care for individuals and families

Ozempic and other GLP-1 drugs are covered only in specific cases